916765-03-2

Upstream product

• 2565-47-1 1-methyl-2,4,6-pyrimidinetrione 
• 916764-89-1 6-chloro-1-(4-methoxybenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione 
• 916764-90-4 6-hydrazinyl-1-(4-methoxybenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione 
• 916765-00-9 6-(2-(biphenyl-4-ylmethylene)hydrazinyl)-1-(4-methoxybenzyl)-3-methylpyrimidine-2,4(1H,3H)-dione 
• 916765-01-0 3-benzyl-2-(biphenyl-4-ylmethyl)-7-(4-methoxybenzyl)-5-methyl-2H-pyrazolo[3,4-d]lpyrimidine-4,6(5H,7H)-dione 
• 4318-56-3 3-methyl-6-chlorouracil 

Downstream Products

• 916765-04-3 3-benzyl-2-(biphenyl-4-ylmethyl)-6-(1-hydroxy-2-methylpropan-2-ylimino)-5-methyl-6,7-dihydro-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 

Relevant academic research and scientific papers

ORGANIC COMPOUNDS

The invention provides novel 7,8-dihydro-imidazo[l,2-α]pyrazolo[4,3-e]pyrimidin-4- one compounds and 7,8,9-trihydro-[lHor 2/f]-pyrimido [l,2-a]pyrazolo[4,3- e]pyrimidin-4(5H)-one compounds, substituted at the 1 or 2 position with C2-g allcyl, C3-9 cycloalkyl, heteroarylalkyl, or substituted arylalkyl, in free, salt or prodrug form, processes for their production, their use as pharmaceuticals, particularly as PDEl inhibitors, and pharmaceutical compositions comprising them.